Download PDF
Synfacts 2022; 18(07): 0805
DOI: 10.1055/s-0041-1737643
Chemistry in Medicine and Biology

A Reversible Covalent Inhibitor Targeting the BCR-ABL Active-Site Lysine

Contributor(s):
Dirk Trauner
,
Julian Maximilian Feilner
› Further Information
    Permissions and Reprints

Key words

BCR-ABL kinase - reversible covalent inhibitors - salicylaldehyde


Publication History

Article published online:
15 June 2022

© 2022. Thieme. All rights reserved

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany